US Stock Insider Trading | United Treatment disclosed 1 insider trading transaction on March 2

robot
Abstract generation in progress

On March 2, 2026, United Therapeutics (UTHR) disclosed one insider transaction. Director Olian Judy D. sold 200 shares on February 27, 2026.

【Recent Insider Transactions】

Disclosure Date Position Name Transaction Date Buy/Sell Quantity Price per Share/USD Total Amount/USD
March 2, 2026 Director Olian Judy D. February 27, 2026 Sell 200 509.55 $10,190
February 25, 2026 Director CAUSEY CHRISTOPHER February 25, 2026 Buy 1,000 119.76 $11,980
February 25, 2026 Director CAUSEY CHRISTOPHER February 25, 2026 Sell 1,000 520.00 $520,000
February 24, 2026 Executive BENKOWITZ MICHAEL February 23, 2026 Buy 5,065 146.03 $739,600
February 24, 2026 Executive BENKOWITZ MICHAEL February 23, 2026 Buy 9,375 117.76 $1,104,000
February 24, 2026 Executive BENKOWITZ MICHAEL February 23, 2026 Sell 14,000 472.13 $6,817,500
February 19, 2026 Executive MAHON PAUL A February 19, 2026 Sell 1,114 477.10 $53,150
February 19, 2026 Executive MAHON PAUL A February 19, 2026 Buy 8,300 146.03 $1,212,000
February 19, 2026 Executive MAHON PAUL A February 19, 2026 Sell 2,100 478.15 $1,004,100
February 19, 2026 Executive MAHON PAUL A February 19, 2026 Sell 288 473.23 $13,630

【Company Profile】

United Therapeutics Corporation was founded in Delaware in 1996. It is a biotechnology company dedicated to developing and commercializing unique products that address unmet medical needs for patients with chronic and life-threatening conditions. Its revenue mainly comes from sales of Remodulin, Tyvaso, and Tadalafil. Their marketing and sales teams work hard to make their products available in authorized countries, primarily through their professional distributors in the U.S. and other international distributors.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin